Drugs / REGN7945
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06669247 | Dec 2024 → Nov 2033 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN7945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06669247 ↗ |
| Action | Activate | “Costimulatory” NCT06669247 ↗ |
| Modality | Monoclonal antibody | “REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT06669247 ↗ |
| Target | CD28 | “Anti-CD28” NCT06669247 ↗ |
| Target | CD38 | “Anti-CD38” NCT06669247 ↗ |